Biofilm production and antibiotic susceptibility of Staphylococcus epidermidis strains from Hidradenitis Suppurativa lesions

被引:31
作者
Ardon, C. B. [1 ,2 ]
Prens, E. P. [1 ]
Fuursted, K. [3 ]
Ejaz, R. N. [2 ]
Shailes, J. [2 ]
Jenssen, H. [2 ]
Jemec, G. B. E. [4 ]
机构
[1] Univ Med Ctr Rotterdam, Dept Dermatol, Erasmus MC, Rotterdam, Netherlands
[2] Roskilde Univ, Dept Sci & Environm, Roskilde, Denmark
[3] Staten Serum Inst, Dept Microbiol & Infect Control, Copenhagen, Denmark
[4] Univ Hosp Zealand, Dept Dermatol, Roskilde, Denmark
关键词
COAGULASE-NEGATIVE STAPHYLOCOCCI; IMMUNE DEFENSE SYSTEM; IN-VITRO; ANTIMICROBIAL SUSCEPTIBILITY; MOLECULAR-MECHANISMS; BACTERIAL BIOFILM; QUANTIFICATION; RESISTANCE; RIFAMPIN; CULTURES;
D O I
10.1111/jdv.15183
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background An aberrant interaction between commensal skin bacteria and the host skin immune system is considered important in the pathogenesis of hidradenitis suppurativa (HS). Objective In this study, we investigated the antibiotic susceptibility and biofilm-forming capabilities of S. epidermidis strains isolated from HS patients. Methods Skin biopsies were taken from active HS lesions such as inflammatory nodules and/or sinuses and non-involved skin from 26 patients and cultured under optimal microbiological conditions for 24 h. Planktonic growth, biofilm production, antibiotic susceptibility and biofilm eradication by clindamycin, doxycycline, rifampicin and tetracycline were tested including a laboratory control strain of S. epidermidis for reference. Results Staphylococcus epidermidis was cultured in 16 of 26 HS patients (62%). In total 27 different S. epidermidis isolates were identified; 16 (59%) from non-involved skin and 11 (41%) from HS lesions. All bacterial strains showed planktonic growth. Twenty-four of 27 (89%) isolates were strong biofilm producers in vitro. The biofilm-forming capability varied amongst the strains from non-involved skin and lesional skin. Twenty-four strains had an intermediate to resistant antibiotic susceptibility to clindamycin (89%). Rifampicin was the most effective antibiotic at inhibiting planktonic growth and at eradication of biofilm (P < 0.05). Conclusion We observed a slight increase in S. epidermidis virulence, characterized by resistance to commonly used antibiotics, increased biofilm production and resistance to biofilm eradication. In particular, the reduced sensitivity to tetracycline and clindamycin, two standard antibiotics in the treatment of HS, is alarming. Rifampicin, also important in HS treatment, showed the greatest efficacy at eradicating the biofilm at low MIC concentrations.
引用
收藏
页码:170 / 177
页数:8
相关论文
共 44 条
[1]   An outbreak of methicillin resistant Staphylococcus epidermidis among neonates in a hospital in Saudi Arabia [J].
Abd El Hafez, Maha ;
Khalaf, Noha G. ;
El Ahmady, Mohamed ;
Abd El Aziz, Ahmed ;
Hashim, Abd El Gawad .
JOURNAL OF INFECTION IN DEVELOPING COUNTRIES, 2011, 5 (10) :692-699
[2]   Innate immune defense system of the skin [J].
Afshar, Maryam ;
Gallo, Richard L. .
VETERINARY DERMATOLOGY, 2013, 24 (01) :32-+
[3]  
Aral M, 2004, RHINOLOGY, V42, P131
[4]   INVITRO INTERACTION BETWEEN RIFAMPIN AND CLINDAMYCIN AGAINST PATHOGENIC COAGULASE-NEGATIVE STAPHYLOCOCCI [J].
ARDITI, M ;
YOGEV, R .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (02) :245-247
[5]   Antimicrobial susceptibility and body site distribution of community isolates of coagulase-negative staphylococci [J].
Cavanagh, Jorunn Pauline ;
Wolden, Runa ;
Heise, Philipp ;
Esaiassen, Eirin ;
Klingenberg, Claus ;
Fredheim, Elizabeth G. Aarag .
APMIS, 2016, 124 (11) :973-978
[6]   Staphylococcus epidermidis pan-genome sequence analysis reveals diversity of skin commensal and hospital infection-associated isolates [J].
Conlan, Sean ;
Mijares, Lilia A. ;
Becker, Jesse ;
Blakesley, Robert W. ;
Bouffard, Gerard G. ;
Brooks, Shelise ;
Coleman, Holly ;
Gupta, Jyoti ;
Gurson, Natalie ;
Park, Morgan ;
Schmidt, Brian ;
Thomas, Pamela J. ;
Otto, Michael ;
Kong, Heidi H. ;
Murray, Patrick R. ;
Segre, Julia A. .
GENOME BIOLOGY, 2012, 13 (07)
[7]  
Costerton JW, 1995, ANNU REV MICROBIOL, V49, P5
[8]   An Update on Medical Treatment Options for Hidradenitis Suppurativa [J].
Deckers, I. E. ;
Prens, E. P. .
DRUGS, 2016, 76 (02) :215-229
[9]  
EUCAST, 2018, EUR COMM ANT SUSC TE
[10]  
Fey PD, 2010, FUTURE MICROBIOL, V5, P917, DOI [10.2217/fmb.10.56, 10.2217/FMB.10.56]